about
Identification of a three-gene expression signature of poor-prognosis breast carcinomaA Review of the Clinical Implications of Breast Cancer BiologyThe Interactions of Obesity, Inflammation and Insulin Resistance in Breast CancerIdentifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomesHigh expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.MALDI-TOF MS analysis of urinary nucleosides.SELDI-TOF-MS proteomics of breast cancer.Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasetsIntegrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomasFractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapyThe marine-derived sipholenol A-4-O-3',4'-dichlorobenzoate inhibits breast cancer growth and motility in vitro and in vivo through the suppression of Brk and FAK signaling.Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues.The differential expression of aqueous soluble proteins in breast normal and cancerous tissues in relation to stage and grade of patientsGrowth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.Agreement on indication for systemic therapy between biopsied tissue and surgical excision specimens in breast cancer patientsBiological Markers Predictive of Invasive Recurrence in DCIS.Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology.Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells.DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancerFKBPL: a marker of good prognosis in breast cancer.Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated PathwayLow E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma.Tumour markers: An overview.Primer: an evidence-based approach to prognostic markers.CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancerExpression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancersUrokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients.Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancerEffect of HER2 status on distant recurrence in early stage breast cancerTissue detection of biomolecular predictors in breast cancer.Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.Correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern IndiaAssessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione.Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practiceMultiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.A lectin-based approach to detecting carcinogenesis in breast tissue
P2860
Q24802692-1454147D-E722-4247-B42E-D90ABFB2531CQ26744288-CCD2667A-C11C-4860-8777-4D2F72E60AF8Q26777775-BBC9D7C7-79EB-420F-BEBB-798E07101D94Q26778675-C9269968-D20C-498F-B129-B1B3159E029BQ27851775-2C18912D-3761-465A-876F-6AABB2A8C2BEQ33215515-3B949656-7E8F-4DBE-A991-2F8ECCABBCF1Q33227849-170C25AE-9FFB-4D97-826A-DDD7C2345B0FQ33361596-44CA52FF-943C-4606-8DE5-7EEBBF2CCCD1Q33382997-D6046301-4CDD-418F-9227-FDE2F06FC57BQ33559079-FBA8A66B-EC55-483C-8450-8B3B08613948Q33568902-6338A683-B9E8-4A3A-975A-747F9FAEF117Q33575622-996814A3-2D17-4B5B-9C6E-2AC3A0119B96Q34336095-D183A3AF-0D18-4EF6-8B32-8734C365D313Q34417001-641EE8BF-ABAD-4A7F-A3FD-CC7F1C47CDC2Q34908845-A1501C1F-0E3D-4F6E-93A8-5711F6A0AB02Q35116141-8284A442-214F-429C-9D43-1ABC6636089DQ35181071-065F3A0A-7B49-491D-9AF2-91090D75255BQ35277008-CBBCC973-1695-4B1B-A673-4F1E4D496A06Q35428525-675E9D8C-D3FE-48D9-9DF7-BF3FEFB8DDBDQ35434433-D781073C-6AE9-490E-8906-96DD247CA904Q35828542-BDA996DC-E830-4F63-BCD0-6131A2BFD347Q35879517-FCB2E889-AC0D-4662-B8CC-1FDF124F5E82Q35906318-C6FC43C4-07EB-4F05-85D3-BBDA06F8FD38Q36147459-C43564A9-B31B-4BBC-A64C-54A452FD021EQ36237072-45568D72-133E-4CF7-875E-33A0C596EADDQ36264719-0F2DF2ED-248D-4663-A66D-6C8EE6C16F9BQ36304030-613B7226-7CB4-4535-AB07-B804BE098030Q36465344-824674C1-6C5C-4818-B74E-79794B544768Q36477512-907E486D-CBAA-4FEF-9594-CE5F8D2B509FQ36490382-0BFFABAB-85C4-4073-9A19-99A5BAFDFAF0Q36502689-88B74DDD-37C2-4F5F-8CEC-BF6474A42731Q36508067-BA7054CA-3762-4B61-A8F9-600B6CE6E1C4Q36530791-3415BB21-BC58-4186-B2D2-392D0E71A46BQ36573836-D02F69D5-5713-4B85-8554-DE20CC261C9EQ36615222-7FFE511C-883F-4545-9EC4-3EB3525F5F53Q36634397-FA0EF074-3AE1-4DA0-B055-FA88E130F979Q36676997-8CECB864-37C5-4F89-B5E0-4DAFDB47C1D1Q36754437-FD088F02-CE92-403A-9B18-30C2CBEE5539Q36816034-DE76CEE0-CDB9-47F2-837C-E939DD08AE11Q36954600-9534B068-1D1D-4B27-92C8-A1EA6D4EC35C
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Prognostic molecular markers in early breast cancer
@ast
Prognostic molecular markers in early breast cancer
@en
Prognostic molecular markers in early breast cancer
@nl
type
label
Prognostic molecular markers in early breast cancer
@ast
Prognostic molecular markers in early breast cancer
@en
Prognostic molecular markers in early breast cancer
@nl
prefLabel
Prognostic molecular markers in early breast cancer
@ast
Prognostic molecular markers in early breast cancer
@en
Prognostic molecular markers in early breast cancer
@nl
P2860
P921
P3181
P356
P1476
Prognostic molecular markers in early breast cancer
@en
P2093
Francisco J Esteva
Gabriel N Hortobagyi
P2860
P2888
P304
P3181
P356
10.1186/BCR777
P407
P577
2004-03-11T00:00:00Z
P5875
P6179
1014097777